普米克令舒和博利康尼联合雾化吸入治疗慢性阻塞性肺病急性加重期的临床观察

Observation on pulmicort repules plus terbutaline inhalation of foggy in the treatment of chronic obstructive pulmonary disease at acute exacerbation phase

目的观察普米克令舒和博利康尼联合雾化吸入对慢性阻塞性肺病急性加重期(AECOPD)的临床疗效。方法58例AECOPD住院患者随机分为两组:观察组30例给予普米克令舒1mg和博利康尼雾化液5mg联合雾化吸入治疗,2次/日;对照组28例给予博利康尼雾化液5mg雾化吸入,甲基强的松龙40mg/日静滴。记录两组患者用药7天前后PaO2、PaCO2、FEV1变化,同时观察不良反应及疗效分析。结果观察组总有效率86.67%,对照组总有效率89.29%,两组疗效相比无显著性差异(P>0.05);两组患者治疗前后PaO2、PaCO2、FEV1均有改善,治疗前后相比有显著性差异(P<0.05),但两组间相互比较无显著性差异(P>0.05);观察组副作用明显少于对照组。结论普米克令舒和博利康尼联合雾化吸入能够改善AECOPD患者肺功能及临床症状,与全身使用糖皮质激素疗效相近,但副作用明显减少。

Objective To observe the clinical effect of pulmicort repulse plus terbutaline inhalation on acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods 58 patients with AECOPD were randomly divided into two groups ： the observed group of 30 patients were given the treatment of pulmicort repulse （ 1mg ） plus terbutaline （ 5mg ） inhalation of foggy twice a day ; the control group of 28 patients were given the treatment of terbutaline （ 5mg ） inhalation of foggy and injection of methylprednisolone （ 40mg ） a day. Recorded the each change of PaO2,PaCO2,FEV1 on the first day and the seventh day, meanwhile observed the side effect as well as the effect analysis. Results The rate of the observed group was 86.67%, while the rate of the control group was 89.29%, and there was no obvious difference between the two groups （ P〉0.05 ）; PaO2, PaCO2,FEV1 of the patients of the two groups both improved, and there was obvious difference after the treatment （ P〈0.05 ）, but there was still no obvious difference between the two groups （ P〉0.05 ）; The side effect of the observed group was obviously less than that of the control group. Conclusion The treatment of pulmicort repulse plus terbutaline inhalation can improve the lung function and the clinical symptom of patients with AECOPD, which is similar to the effect of glucocorticoid intravenously but obviously has less side effect.